Chugai To Market, Test Tarceva In Japan As Iressa Alternative (Japan)
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical of Japan plans to launch Tarceva (erlotinib hydrochloride) for treating non-small cell lung cancer by the end of the year. Chugai's Swiss parent, Roche, sells the drug elsewhere and Chugai plans to begin Phase II clinical trials on the drug for treating pancreatic cancer, an indication already approved elsewhere. Chugai expects healthy sales in Japan because of problems AstraZeneca had with its similar drug, Iressa (gefitinib). (Click here for more - may require paid subscription